deltatrials
Active Not Recruiting PHASE1 INTERVENTIONAL 1-arm NCT02537418

Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens

A Phase IB Study of Durvalumab (MEDI4736) With or Without Tremelimumab in Patients With Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens

Sponsor: AstraZeneca

Conditions Solid Malignancies
Interventions durvalumab tremelimumab
Updated 20 times since 2017 Last updated: Aug 18, 2025 Started: Oct 16, 2015 Primary completion: Jul 20, 2018 Completion: Jan 30, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Solid Malignancies and is currently ongoing. AstraZeneca leads this study, which shows 20 recorded versions since 2015 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Oct 2017 · 8 months · monthly snapshot~Oct 2017 – ~Jun 2018 · 8 months · monthly snapshot~Jun 2018 – ~Oct 2018 · 4 months · monthly snapshot~Oct 2018 – ~Jul 2019 · 9 months · monthly snapshot~Jul 2019 – ~Apr 2020 · 9 months · monthly snapshot~Apr 2020 – ~May 2020 · 30 days · monthly snapshot~May 2020 – ~Jun 2020 · 31 days · monthly snapshot~Jun 2020 – ~Jan 2021 · 7 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Feb 2022 · 11 months · monthly snapshot~Feb 2022 – ~Sep 2022 · 7 months · monthly snapshot~Sep 2022 – ~Feb 2023 · 5 months · monthly snapshot~Feb 2023 – ~Sep 2023 · 7 months · monthly snapshot~Sep 2023 – ~Mar 2024 · 6 months · monthly snapshot~Mar 2024 – ~Jul 2024 · 4 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Mar 2025 · 6 months · monthly snapshot~Mar 2025 – ~Sep 2025 · 6 months · monthly snapshot~Sep 2025 – present · 12 months · monthly snapshot

Change History

20 versions recorded

  1. Sep 2025 — Present [monthly]

    Active Not Recruiting PHASE1

  2. Mar 2025 — Sep 2025 [monthly]

    Active Not Recruiting PHASE1

  3. Sep 2024 — Mar 2025 [monthly]

    Active Not Recruiting PHASE1

  4. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE1

  5. Mar 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE1

▶ Show 15 earlier versions

  1. Sep 2023 — Mar 2024 [monthly]

    Active Not Recruiting PHASE1

  2. Feb 2023 — Sep 2023 [monthly]

    Active Not Recruiting PHASE1

  3. Sep 2022 — Feb 2023 [monthly]

    Active Not Recruiting PHASE1

  4. Feb 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE1

  5. Mar 2021 — Feb 2022 [monthly]

    Active Not Recruiting PHASE1

  6. Jan 2021 — Mar 2021 [monthly]

    Active Not Recruiting PHASE1

  7. Jun 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1

  8. May 2020 — Jun 2020 [monthly]

    Active Not Recruiting PHASE1

  9. Apr 2020 — May 2020 [monthly]

    Active Not Recruiting PHASE1

  10. Jul 2019 — Apr 2020 [monthly]

    Active Not Recruiting PHASE1

  11. Oct 2018 — Jul 2019 [monthly]

    Active Not Recruiting PHASE1

  12. Jun 2018 — Oct 2018 [monthly]

    Active Not Recruiting PHASE1

  13. Oct 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  14. Feb 2017 — Oct 2017 [monthly]

    Recruiting PHASE1

  15. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1

    First recorded

Oct 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AstraZeneca
  • Canadian Cancer Trials Group
Data source: Canadian Cancer Trials Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations